-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Huadong Medicine welcomes good news in the field of oral hypoglycemic drugs.
Figure 1: Information of Huadong Medicine's over-evaluated products
Source: NMPA official website
Pioglitazone hydrochloride tablets are thiazolidinedione insulin sensitizers, which mainly reduce blood sugar by increasing the sensitivity of target cells to insulin
Figure 2: Sales of pioglitazone hydrochloride tablets
Source: Mi Nei.
According to data from Meinenet, in the last three years, the sales of pioglitazone hydrochloride tablets in China’s urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have remained above 500 million yuan in 2020.
Figure 3: East China's next blockbuster oral hypoglycemic drug approved
Source: Meinenet MED2.
In June of this year, East China's Metformin Enpagliflozin Tablets (I) was approved for the first imitation, adding a major player to the company's oral hypoglycemic product line
Source: CDE official website, Minet database
The review data statistics are as of August 20, if there are any errors or omissions, please correct me